Hyperthyroid and thyroid carcinoma patients treated with radioactive 131I (RAI) are a potential source of external and internal exposure to members of the public, to medical staff and especially to family members, who are in close contact with these patients. The relationship between radiation dose rates and various clinical parameters, including gender, age, thyroid size and weight, and iodine uptake, was assessed. Dose rates were measured on eight patients with thyroid carcinoma after total or subtotal thyroidectomy and on six patients with hyperthyroidism. All measurements were taken at 1 m from the patient on two levels—anterior to the neck and body center. Dose rates were measured at three or four times—at the time of RAI administration, and after 24 h, 48 h, and 168 h. Based on these measurements, retention curves were obtained. The effective half-life was derived by fitting an exponential equation and was estimated to be 12.8 h.

References

References
1.
Cappelen
,
T.
, and
Unhjem
,
J. F.
,
2009
, “
Use of 131-Iodine and the Risk of Radiation Exposure: Potential Hazards to the Patient and Other People
,”
Comprehensive Handbook of Iodine
,
V. R.
Preedy
,
G. N.
Burrow
, and
R.
Watson
, eds.,
Academic Press
,
San Diego, CA
, Chap. 100.
2.
McDougall
,
I. R.
,
1992
,
Thyroid Disease in Clinical Practice
,
Chapman & Hall
,
London, UK
.
3.
ICRP
,
1988
,
Radiation Dose to Patients From Radiopharmaceuticals
,
Elsevier Science
, Oxford,
UK
.
4.
Ministry of Health, 2002, “
Regulatory Guide—Release of Patients Administered Iodine 131
,” Ministry of Health 0064/2002, Jerusalem, Israel (in Hebrew).
5.
NCRP
,
2006
,
Management of Radionuclide Therapy Patients
,
NCRP
,
Bethesda, MD
, Report No. 155.
6.
Thermo Scientific
, 2007, “
Bicron Micro Rem Tissue Equivalent Survey Meter
,” Specification Sheet, Thermo Scientific, Erlangen, Germany.
7.
Willegaignon
,
J.
,
Guimaraes
,
M. I. C.
,
Malvestiti
,
L. F.
,
Sordi
,
G. M. A. A.
,
Sapienza
,
M. T.
,
Neto
,
G. C.
, and
Marone
,
M.
,
2005
, “
Monitoramento de Pacientes em Medicine Nuclear
,” Anais do X Congresso Brasileiro de Física Médica, Salvador, Brazil, June 25–26, Paper No. 19.
8.
Willegaignon
,
J.
,
Malvestiti
,
L. F.
,
Guimaraes
,
M. I. C.
,
Sapienza
,
M. T.
,
Endo
,
I. S.
,
Neto
,
G. C.
,
Marone
,
M.
, and
Sordi
,
G. M. A. A.
,
2006
, “
131I Effective Half-Life (Teff) for Patients With Thyroid Cancer
,”
Health Phys.
,
91
(
2
), pp.
119
122
.
You do not currently have access to this content.